Make 150 High yield mcqs for saudi pharmacy licence examination for doctor of pharmacy regarding Saudi laws, regulations, ethnics, everything in detail no pdf
Searching the Web
Saudi pharmacy licence examination SPLE topics laws regulations ethics PharmD 2024 2025
Searching the Web
Saudi Commission Health Specialties pharmacy laws regulations controlled substances drug registration KSA
Reading Web Page
https://www.sfda.gov.sa/en/regulations?keys=®ulation_type…
Searching the Web
Saudi pharmacy practice laws SFDA drug dispensing controlled substances narcotic regulations pharmacist duties KSA
Reading Web Page
https://www.sfda.gov.sa/sites/default/files/2021-09/Drug1211…
Now I have enough information to generate the full 150 high-yield MCQs. Let me compile them from my knowledge of Saudi pharmacy laws, SFDA regulations, SCFHS rules, controlled substances laws, pharmacy ethics, and all related areas.
150 High-Yield MCQs: Saudi Pharmacy Licence Examination (SPLE)
Saudi Laws, Regulations & Ethics - Doctor of Pharmacy
SECTION 1: SFDA - Saudi Food and Drug Authority (Q1-20)
Q1. The Saudi Food and Drug Authority (SFDA) was established in which year?
- A) 1999
- B) 2001
- C) 2003
- D) 2005
Explanation: The SFDA was established by Royal Decree in 2003 as an independent regulatory authority reporting directly to the President of the Council of Ministers.
Q2. Which of the following is NOT under the regulatory jurisdiction of the SFDA?
- A) Pharmaceutical products
- B) Medical devices
- C) Medical education and training
- D) Cosmetics
Explanation: Medical education and training fall under the Saudi Commission for Health Specialties (SCFHS). The SFDA regulates drugs, food, medical devices, cosmetics, and pesticides.
Q3. Which body is responsible for licensing and classifying health professionals including pharmacists in Saudi Arabia?
- A) Ministry of Health (MOH)
- B) SFDA
- C) Saudi Commission for Health Specialties (SCFHS)
- D) Saudi Drug and Narcotic Control Committee
Explanation: The SCFHS is responsible for classifying, registering, and licensing all health practitioners in Saudi Arabia, including pharmacists.
Q4. A drug must be registered with SFDA before marketing in Saudi Arabia. Which of the following is the correct description of this requirement?
- A) Optional for generic drugs
- B) Only required for imported drugs
- C) Mandatory for all pharmaceutical products including generics and imports
- D) Required only for Schedule I substances
Explanation: All pharmaceutical products - brand, generic, local, and imported - must be registered with the SFDA before being marketed in Saudi Arabia.
Q5. The SFDA drug registration dossier format follows which international standard?
- A) ICH CTD (Common Technical Document)
- B) FDA NDA format exclusively
- C) EMA format exclusively
- D) ICH CTD format
Explanation: Saudi Arabia follows the ICH CTD (Common Technical Document) format for drug registration submissions to the SFDA.
Q6. What is the maximum validity period for a drug registration certificate issued by SFDA?
- A) 1 year
- B) 3 years
- C) 5 years
- D) 10 years
Explanation: SFDA drug registration certificates are valid for 5 years and must be renewed before expiry.
Q7. Which classification system does the SFDA use for drug scheduling/classification?
- A) DEA schedules I-V (US)
- B) SFDA's own classification based on MOH guidelines
- C) WHO essential medicines list
- D) British National Formulary classification
Explanation: SFDA uses its own regulatory classification system guided by MOH policies, categorizing drugs as prescription-only, OTC, controlled, etc.
Q8. A pharmaceutical company wishes to advertise a prescription drug directly to consumers in Saudi Arabia. This is:
- A) Permitted if approved by MOH
- B) Permitted for pharmacists only
- C) Permitted if the drug is registered with SFDA
- D) Prohibited - direct-to-consumer advertising of prescription drugs is not allowed
Explanation: Direct-to-consumer advertising of prescription-only medications is prohibited in Saudi Arabia. Promotion is restricted to healthcare professionals.
Q9. Pharmacovigilance reporting in Saudi Arabia is coordinated by which body?
- A) MOH only
- B) WHO
- C) SFDA
- D) SCFHS
Explanation: The SFDA is the national authority for pharmacovigilance in Saudi Arabia, and all suspected adverse drug reactions (ADRs) should be reported to the SFDA.
Q10. A pharmacist dispenses a drug that is later found to be counterfeit. Who bears primary regulatory responsibility for monitoring counterfeit drugs in the market?
- A) MOH
- B) Saudi Customs
- C) SFDA
- D) Ministry of Commerce
Explanation: The SFDA is responsible for detecting and combating counterfeit and substandard drugs in the Saudi market.
Q11. According to SFDA regulations, the labeling of pharmaceutical products in Saudi Arabia must be in:
- A) English only
- B) Arabic only
- C) Both Arabic and English
- D) Any GCC official language
Explanation: SFDA requires all pharmaceutical product labels sold in Saudi Arabia to be in both Arabic and English.
Q12. A new drug application (NDA) submitted to SFDA for a locally manufactured drug requires which of the following?
- A) Only clinical data from the manufacturer
- B) GMP certificate is optional
- C) Full CTD dossier including quality, safety, and efficacy data with valid GMP certificate
- D) Only bioequivalence data
Explanation: Local manufacturers must submit a complete CTD dossier covering quality (Module 3), non-clinical (Module 4), and clinical (Module 5) data, along with a valid GMP certificate.
Q13. Post-marketing surveillance (PMS) obligations in Saudi Arabia require marketing authorization holders to:
- A) Only report deaths related to the drug
- B) Submit annual sales reports only
- C) Report all serious and unexpected adverse drug reactions to SFDA
- D) Wait until 5 years post-launch before reporting
Explanation: MAHs must have pharmacovigilance systems and report serious/unexpected ADRs to the SFDA promptly, following the SFDA pharmacovigilance guidelines.
Q14. Which of the following requires a special import permit from SFDA beyond standard drug registration?
- A) Paracetamol tablets
- B) Antihistamines
- C) Antibiotics
- D) Narcotic and psychotropic substances
Explanation: Importing narcotic and psychotropic substances requires a special import license/permit from the SFDA in addition to standard drug registration.
Q15. The SFDA Good Manufacturing Practice (GMP) inspection is required for:
- A) Retail pharmacies only
- B) Drug wholesale warehouses only
- C) Pharmaceutical manufacturing facilities
- D) Community pharmacies
Explanation: GMP inspections apply to pharmaceutical manufacturing facilities. The SFDA conducts GMP inspections both locally and for overseas manufacturers supplying the Saudi market.
Q16. A pharmacy in Riyadh wishes to sell a newly approved OTC herbal product. Which action is required?
- A) No registration needed for herbal products
- B) Only MOH approval needed
- C) SFDA registration is required for herbal and health products
- D) Only SCFHS approval needed
Explanation: Herbal and health products (dietary supplements, traditional medicines) must be registered with the SFDA before they can be marketed in Saudi Arabia.
Q17. According to SFDA regulations, which body must approve pricing for pharmaceutical products in Saudi Arabia?
- A) Ministry of Commerce
- B) SFDA
- C) MOH
- D) SCFHS
Explanation: The SFDA is responsible for approving and regulating the pricing of pharmaceutical products in Saudi Arabia through its pharmaceutical pricing policy.
Q18. What is the regulatory status of generic drugs in Saudi Arabia regarding bioequivalence (BE)?
- A) BE studies are not required for generics
- B) Only dissolution testing is required
- C) BE studies are mandatory to demonstrate therapeutic equivalence to the reference product
- D) BE is required only for injections
Explanation: Saudi Arabia follows international standards requiring bioequivalence studies for generic drug approval to ensure therapeutic equivalence to the innovator/reference product.
Q19. Parallel importation of pharmaceutical products in Saudi Arabia is:
- A) Freely permitted for registered products
- B) Allowed if cheaper for patients
- C) Regulated and requires specific SFDA authorization
- D) Completely prohibited
Explanation: Parallel importation requires specific SFDA authorization; it is not freely permitted even for products already registered in Saudi Arabia.
Q20. A drug that has been recalled by a manufacturer must be reported to which authority in Saudi Arabia?
- A) MOH
- B) Ministry of Commerce
- C) SFDA
- D) SCFHS
Explanation: Drug recalls must be coordinated with and reported to the SFDA, which oversees the recall process to protect public health.
SECTION 2: Controlled Substances & Narcotic Regulations (Q21-45)
Q21. According to Saudi regulations, who is authorized to prescribe narcotic and psychotropic substances?
- A) Any registered healthcare professional
- B) Pharmacists with special license
- C) Licensed physicians, dentists, and veterinarians practicing in Saudi Arabia
- D) Nurses with authorization
Explanation: Only licensed physicians, dentists, and veterinarians authorized to practice in Saudi Arabia may prescribe narcotic and psychotropic substances.
Q22. A prescription for a narcotic drug is presented to a pharmacist. After dispensing, what must the pharmacist do with the prescription?
- A) Return it to the patient
- B) Destroy it after 30 days
- C) Send it to MOH
- D) Retain it in the pharmacy, recording the date of dispensing and register number
Explanation: Per Saudi regulations (Article 30), narcotic prescriptions must be retained in the pharmacy after dispensing, annotated with the date of dispensing and prescription register number.
Q23. Narcotic and psychotropic substances in Saudi Arabia must be stored in:
- A) Any locked cabinet
- B) Refrigerator only
- C) A secure, dedicated locked safe/cabinet separate from other medications
- D) Standard shelves with restricted access
Explanation: Saudi regulations require narcotic and psychotropic substances to be stored in a secure, dedicated locked safe with access restricted to authorized personnel.
Q24. What is the maximum supply allowed for a narcotic prescription dispensed in a Saudi pharmacy for outpatient use?
- A) One week
- B) As determined by the physician's prescription, typically not exceeding what the prescription specifies, with quantity limits per MOH policy
- C) Three months
- D) One year
Explanation: The quantity dispensed must match the prescription, and Saudi regulations limit narcotic dispensing to what is prescribed within MOH-defined quantity limits, typically covering the treatment period.
Q25. A private pharmacy applies for a license to sell narcotic substances. Approval must be obtained from:
- A) SCFHS only
- B) Ministry of Commerce
- C) MOH only
- D) Health Affairs in the region/province AND SFDA
Explanation: Applications for private pharmacies to sell narcotics require approval from the Health Affairs (Health Investment Development Department) in the region and the SFDA.
Q26. Which of the following is correct regarding the Saudi pharmacist responsible for narcotic custody in a pharmacy?
- A) Can be any nationality
- B) Must be a SCFHS Fellow
- C) Must be a Saudi national
- D) Must hold a PhD in pharmacy
Explanation: Saudi regulations require that the pharmacist responsible for the custody of narcotic and psychotropic substances in government and private establishments must be a Saudi national.
Q27. Annual estimation of narcotic drug requirements for MOH establishments is submitted to:
- A) SFDA directly
- B) Medical supply department in the region/province for review, then to SFDA
- C) Ministry of Finance
- D) SCFHS
Explanation: MOH-supervised establishments submit their annual narcotic needs estimates through the medical supply department in the region/province, which audits them before submission to the SFDA.
Q28. A doctor in a private clinic wishes to possess and dispense narcotics from their clinic. Which condition is FALSE?
- A) The clinic license from MOH must be valid
- B) The clinic must have an SFDA-approved annual requirement
- C) Narcotics must be under physician supervision or a Saudi pharmacist/technician
- D) The doctor may prescribe any narcotic regardless of MOH-specified ambulatory medications
Explanation: Possession in private clinics is limited ONLY to ambulatory medications specified/approved by the Minister of Health (Article 24D).
Q29. According to Saudi narcotic regulations, sale in licensed private pharmacies is restricted to:
- A) Any registered narcotic drug at the pharmacy's discretion
- B) Only narcotics registered and priced by SFDA, dispensed only with systemic prescriptions
- C) Any drug requested by the patient
- D) Narcotics available in neighboring GCC countries
Explanation: Private pharmacies may only sell narcotic and psychotropic substances that are registered AND priced by SFDA, and dispensing is exclusively to patients with valid systemic prescriptions.
Q30. A pharmacist discovers a discrepancy in the narcotic drug register (quantity received vs. quantity dispensed). The correct action is:
- A) Self-correct and continue
- B) Ignore minor discrepancies
- C) Ask the next pharmacist to handle it
- D) Report immediately to the supervisor and the relevant authority (MOH/SFDA)
Explanation: Any discrepancy in narcotic records is a serious regulatory issue requiring immediate reporting to supervisors and relevant authorities. Failing to report is a violation.
Q31. Which of the following best describes Saudi Arabia's scheduling of tramadol?
- A) OTC analgesic
- B) Prescription-only, non-controlled
- C) Controlled substance (psychotropic) requiring special prescription
- D) Banned substance not available in Saudi Arabia
Explanation: Tramadol is classified as a psychotropic/controlled substance in Saudi Arabia and requires a controlled substance prescription, not an ordinary prescription.
Q32. Disposal of expired or unused narcotic substances in a Saudi pharmacy must be:
- A) Flushed down the drain
- B) Disposed with regular waste
- C) Sold back to the supplier
- D) Conducted under official supervision and documented per SFDA/MOH procedures
Explanation: Destruction/disposal of narcotic substances must be done officially, under supervision of authorized personnel, with proper documentation as required by Saudi regulations.
Q33. A patient presents a foreign (non-Saudi) prescription for a controlled substance. A Saudi pharmacist should:
- A) Dispense if it looks legitimate
- B) Dispense with a pharmacist annotation
- C) Dispense if the patient is a tourist
- D) Not dispense - only prescriptions from Saudi-licensed prescribers are valid for controlled substances
Explanation: Narcotic prescriptions must be from physicians authorized to practice in Saudi Arabia. Foreign prescriptions are not valid for dispensing controlled substances in Saudi Arabia.
Q34. Travelers entering Saudi Arabia with controlled substances for personal medical use must:
- A) Declare at customs verbally
- B) No action required if within 30-day supply
- C) Carry original pharmacy label only
- D) Obtain an online clearance permit from the SFDA Controlled Drugs System (CDS) prior to arrival
Explanation: Per SFDA regulations, travelers bringing controlled medications must obtain a travel permit through the SFDA Controlled Drugs System portal before entering Saudi Arabia, for a maximum 1-month personal supply.
Q35. Benzodiazepines in Saudi Arabia are classified as:
- A) Over-the-counter medications
- B) Non-controlled prescription drugs
- C) Psychotropic/controlled substances requiring a controlled substance prescription
- D) Banned substances
Explanation: Benzodiazepines are classified as psychotropic substances in Saudi Arabia and require controlled substance prescriptions; they cannot be dispensed on regular prescriptions.
Q36. Which of the following statements about narcotic drug registers in Saudi pharmacies is CORRECT?
- A) Electronic records alone are sufficient without a physical register
- B) Only outgoing (dispensed) quantities need recording
- C) Records can be maintained by any pharmacy staff
- D) All receipts and disbursements must be meticulously recorded with dates, quantities, and patient details
Explanation: Saudi regulations require comprehensive narcotic registers tracking all receipts, disbursements, quantities, dates, patient details, and prescription numbers. Both receipt and dispensing must be documented.
Q37. A pharmacist is asked by a physician to provide them with narcotics "for future prescriptions" without individual patient prescriptions. The pharmacist should:
- A) Comply as the physician is licensed
- B) Comply if the quantity is small
- C) Ask for written confirmation
- D) Refuse - narcotics may only be dispensed against individual valid patient prescriptions
Explanation: Narcotic drugs must only be dispensed against individual patient-specific prescriptions. Bulk provision to a physician without patient prescriptions is a serious violation.
Q38. A psychotropic substance is found missing from the pharmacy's narcotic cabinet. The immediate required action is:
- A) Replace the missing quantity from another stock
- B) Document and wait for month-end reconciliation
- C) Inform only the pharmacy owner
- D) Immediately report to the concerned authority (MOH/SFDA/police) and document the incident
Explanation: Any theft or unexplained loss of controlled substances is a criminal matter requiring immediate reporting to the relevant authorities in Saudi Arabia.
Q39. Methylphenidate (Ritalin) is used for ADHD. In Saudi Arabia, this drug is classified as:
- A) OTC drug
- B) Regular prescription drug
- C) Controlled/psychotropic substance requiring special prescription
- D) Banned drug not available in KSA
Explanation: Methylphenidate is a psychostimulant and is classified as a controlled substance in Saudi Arabia, requiring a controlled substance prescription.
Q40. Under Saudi regulations, who can act as a custodian for narcotic substances in a government hospital pharmacy?
- A) Any health professional
- B) A non-Saudi pharmacist with experience
- C) Only the pharmacy director
- D) A Saudi pharmacist or Saudi pharmacy technician designated by name
Explanation: Saudi regulations specifically require that the individual responsible for narcotic custody in government bodies must be a named Saudi pharmacist or Saudi pharmacy technician.
Q41. The valid period of a narcotic prescription in Saudi Arabia is:
- A) 3 days
- B) 15 days
- C) Specified by MOH regulations - typically valid for a short defined period (e.g., 7-30 days depending on the substance)
- D) 1 year like any prescription
Explanation: Saudi narcotic prescriptions have limited validity as defined by MOH policy, much shorter than regular prescriptions, to prevent stockpiling and misuse.
Q42. A narcotic drug cannot be dispensed more than once from a single prescription in Saudi Arabia. This refers to:
- A) The pharmacist's preference
- B) The principle of single dispensing - narcotic prescriptions cannot be refilled
- C) Only applicable for Schedule I drugs
- D) Only applicable in private pharmacies
Explanation: Narcotic and psychotropic substance prescriptions in Saudi Arabia are single-use - they cannot be refilled or partially dispensed on multiple occasions.
Q43. Import of narcotic substances into Saudi Arabia requires approval from:
- A) Ministry of Commerce
- B) Saudi Customs alone
- C) MOH only
- D) SFDA with a valid import license
Explanation: Importing narcotics and psychotropic substances requires a specific import license issued by the SFDA with documentation proving the substances are for legitimate medical/scientific purposes.
Q44. A pharmaceutical company that manufactures a psychotropic substance locally in Saudi Arabia must:
- A) Only register the product with SFDA
- B) Obtain GMP certification only
- C) Obtain SFDA registration for the product and comply with all narcotic manufacturing regulations including annual quantity approvals
- D) Only comply with MOH standards
Explanation: Local manufacturers of psychotropic substances must register products with SFDA, maintain GMP compliance, obtain annual production quantity approvals, and comply with all narcotic manufacturing regulations.
Q45. Which statement regarding morphine prescribing in Saudi Arabia is CORRECT?
- A) Any licensed physician can prescribe unlimited quantities
- B) It can be prescribed on regular prescriptions
- C) Only oncologists can prescribe morphine
- D) It requires a special controlled substance prescription with specific data fields and is subject to quantity/duration limits
Explanation: Morphine is a narcotic requiring the special controlled substance prescription form, with quantity limits and specific data requirements per Saudi narcotic regulations.
SECTION 3: Pharmacy Practice & Licensing (Q46-70)
Q46. To practice pharmacy in Saudi Arabia, a pharmacist must be registered with which body?
- A) SFDA
- B) MOH only
- C) Saudi Commission for Health Specialties (SCFHS)
- D) Ministry of Commerce
Explanation: Pharmacists must be classified and registered with SCFHS before practicing in Saudi Arabia. SCFHS issues membership certificates that are required for licensing.
Q47. A pharmacy in Saudi Arabia must be technically supervised by:
- A) Any licensed physician
- B) A pharmacy technician
- C) A licensed pharmacist
- D) A nurse with prescribing authority
Explanation: Saudi pharmacy law requires that every pharmacy be technically supervised by a licensed pharmacist. The pharmacist holds legal and professional responsibility.
Q48. The opening of a new pharmacy in Saudi Arabia requires a license from:
- A) SFDA alone
- B) SCFHS alone
- C) Ministry of Commerce alone
- D) MOH (Health Affairs in the region) plus meeting all regulatory requirements
Explanation: Opening a new pharmacy requires a pharmacy license from the Ministry of Health (via regional Health Affairs offices), in addition to meeting all SFDA and SCFHS requirements.
Q49. A pharmacist notices that a prescription appears to be forged. The appropriate action is:
- A) Dispense and document
- B) Ask the patient to get a new prescription
- C) Dispense only if the medication is OTC
- D) Refuse to dispense and report to the appropriate authority
Explanation: Dispensing against a forged prescription is illegal. The pharmacist must refuse dispensing and report suspected fraud to appropriate authorities.
Q50. In Saudi Arabia, prescription-only medicines (POM) can be dispensed:
- A) Without a prescription if the pharmacist deems it appropriate
- B) Based on the patient's verbal request if they claim a physician consultation
- C) Only with a valid prescription from a licensed prescriber
- D) Based on previous prescription history
Explanation: POM medications require a valid written prescription from a licensed prescriber. Dispensing POMs without a prescription is a violation of Saudi pharmacy law.
Q51. A pharmacist receives a prescription that is unclear or ambiguous. The correct action is:
- A) Use professional judgment and dispense the closest product
- B) Ask the patient what they think it says
- C) Contact the prescribing physician for clarification before dispensing
- D) Return the prescription without dispensing
Explanation: The pharmacist's professional obligation is to clarify ambiguous prescriptions by contacting the prescriber - this protects patient safety and is a fundamental pharmaceutical care principle.
Q52. Which of the following is a legal requirement for a valid prescription in Saudi Arabia?
- A) Patient's passport number
- B) Pharmacist's signature
- C) Prescriber's name, signature, date, and patient information
- D) Insurance company name
Explanation: A valid Saudi prescription must include the prescriber's full name, specialty, license number, signature, date, and complete patient information (name, age, diagnosis when required).
Q53. A pharmacist working in a community pharmacy is asked to provide medication counseling. This is:
- A) Optional at the pharmacist's discretion
- B) Only required for controlled substances
- C) The responsibility of the physician, not the pharmacist
- D) A professional and legal obligation of the pharmacist
Explanation: Medication counseling is a core professional and ethical obligation of pharmacists under Saudi pharmacy practice standards and SCFHS professional codes.
Q54. The practice of substituting a prescribed brand medication with a generic equivalent in Saudi Arabia:
- A) Is freely permitted without restriction
- B) Is completely prohibited
- C) Requires patient consent only
- D) Is regulated and requires prescriber approval unless the prescription specifically allows substitution
Explanation: Generic substitution in Saudi Arabia requires prescriber approval or permission indicated on the prescription, unless institutional policy specifically allows pharmacist-initiated substitution.
Q55. A pharmacist identifies a potentially dangerous drug interaction in a patient's prescription. The appropriate action is:
- A) Dispense and add a warning label
- B) Refuse to dispense without explanation
- C) Ask the patient to return later
- D) Contact the prescriber, inform the patient, and document the intervention
Explanation: Pharmacists have a professional and legal duty to identify and act on drug interactions - this includes contacting the prescriber, counseling the patient, and documenting the clinical intervention.
Q56. Which of the following is NOT a legitimate role of a clinical pharmacist in a Saudi hospital?
- A) Therapeutic drug monitoring (TDM)
- B) Drug information services
- C) Pharmacokinetic dosing consultations
- D) Independently diagnosing and treating disease
Explanation: Pharmacists in Saudi Arabia, even in clinical roles, cannot independently diagnose diseases or initiate treatment without a physician's involvement. Diagnosis remains the physician's domain.
Q57. In Saudi Arabia, dispensing of medications to hospital inpatients must be documented in:
- A) The patient's personal notebook
- B) Any available paper
- C) The official medication administration record (MAR) and pharmacy dispensing records
- D) Only in the physician's notes
Explanation: Hospital inpatient medication dispensing must be documented in formal medication administration records maintained per hospital accreditation and MOH standards.
Q58. A pharmacist in Saudi Arabia dispenses a medication error that results in patient harm. This may result in:
- A) Only a verbal warning
- B) No action if the error was unintentional
- C) Civil liability only
- D) Professional disciplinary action by SCFHS, civil liability, and potentially criminal liability
Explanation: Dispensing errors causing patient harm can lead to SCFHS disciplinary proceedings (license suspension/revocation), civil lawsuits for damages, and in cases of gross negligence, criminal prosecution.
Q59. A patient requests a medication that is available OTC in other countries but is prescription-only in Saudi Arabia. The pharmacist should:
- A) Dispense it as it is OTC globally
- B) Dispense and document
- C) Refuse and explain that it requires a prescription in Saudi Arabia
- D) Refer to SFDA for guidance immediately
Explanation: Drug scheduling in Saudi Arabia is determined by Saudi regulations, not international classification. A prescription-only classification in Saudi Arabia must be followed regardless of other countries' rules.
Q60. The minimum qualification required to practice as a pharmacist in Saudi Arabia is:
- A) Diploma in pharmacy (2 years)
- B) Associate degree
- C) Bachelor of Pharmacy (B.Pharm) or Doctor of Pharmacy (PharmD)
- D) Any healthcare degree with pharmacy training
Explanation: SCFHS requires a minimum of a Bachelor of Pharmacy degree from an accredited institution for registration as a pharmacist. Many positions, especially clinical, now require PharmD.
Q61. A non-Saudi pharmacist wishing to practice in Saudi Arabia must:
- A) Only show their home country license
- B) Contact the Ministry of Commerce
- C) Only pass the SCFHS exam
- D) Register with SCFHS, obtain classification, pass required examinations, and obtain a work visa/iqama
Explanation: Foreign pharmacists must complete SCFHS classification and registration, pass required qualifying examinations (SPLE), obtain a professional license, and fulfill visa/Iqama requirements.
Q62. Which act is considered a violation of pharmacy practice law in Saudi Arabia?
- A) Counseling patients on OTC medications
- B) Providing drug information
- C) Dispensing a prescription drug without a valid prescription
- D) Recommending generic substitution with prescriber consent
Explanation: Dispensing prescription drugs without a valid prescription is a serious legal violation in Saudi Arabia, subject to penalties including license suspension and criminal charges.
Q63. Continuing Professional Development (CPD) for pharmacists in Saudi Arabia is overseen by:
- A) Individual employers
- B) SFDA
- C) SCFHS
- D) Saudi Pharmaceutical Society
Explanation: SCFHS oversees the continuing professional development requirements for all health professionals including pharmacists in Saudi Arabia.
Q64. Which of the following best describes the concept of "pharmaceutical care" as applied in Saudi pharmacy practice?
- A) Only dispensing medications efficiently
- B) Administering medications to patients
- C) Managing the pharmacy's finances
- D) Patient-centered practice aimed at achieving definite therapeutic outcomes and improving quality of life
Explanation: Pharmaceutical care, the standard of pharmacy practice endorsed by SCFHS, is the responsible provision of drug therapy to achieve definite outcomes that improve a patient's quality of life.
Q65. A community pharmacist in Saudi Arabia discovers that a regular patient is taking multiple medications from different prescribers that cause dangerous drug interactions. The pharmacist should:
- A) Ignore it as it is not the pharmacist's problem
- B) Stop dispensing all the patient's medications
- C) Dispense all and just counsel the patient
- D) Review the medications, counsel the patient, and contact the prescribers as appropriate
Explanation: Medication reconciliation and management of drug-drug interactions is a core pharmacist responsibility - it requires intervention, counseling, and prescriber communication.
Q66. An expired pharmaceutical product found on pharmacy shelves in Saudi Arabia should be:
- A) Discounted and sold before disposal
- B) Returned to the supplier without documentation
- C) Mixed with current stock if the expiry is minor
- D) Immediately removed from dispensing stock, quarantined, and disposed of per SFDA/MOH procedures
Explanation: Expired medications must be removed from active stock, quarantined, documented, and disposed of through the regulated pharmaceutical waste disposal system.
Q67. The Saudi National Drug Policy's goal regarding essential medicines aims to:
- A) Maximize pharmaceutical industry profits
- B) Import all drugs from a single country
- C) Eliminate generics from the market
- D) Ensure availability, affordability, and appropriate use of essential medicines
Explanation: The Saudi National Drug Policy, aligned with WHO principles, aims to ensure that essential medicines are available, affordable, of good quality, and appropriately used across the Kingdom.
Q68. Which of the following is a requirement for hospital pharmacy accreditation in Saudi Arabia?
- A) 24-hour pharmacy service is optional
- B) Only physician approval is needed
- C) Pharmacist presence is optional after hours
- D) Compliance with Central Board for Accreditation of Healthcare Institutions (CBAHI) or JCI standards
Explanation: Hospital pharmacies in Saudi Arabia must comply with standards set by CBAHI (the national accreditation body) or JCI for international hospitals, which include specific pharmacy service requirements.
Q69. The practice of "polypharmacy" in elderly Saudi patients primarily falls under the pharmacist's duty to:
- A) Increase drug sales
- B) Only report to the physician
- C) Avoid any patient interaction
- D) Conduct medication reviews and identify opportunities for deprescribing to optimize therapy
Explanation: Pharmacists have a key role in managing polypharmacy in the elderly through comprehensive medication reviews, identifying interactions, duplications, and inappropriate medications.
Q70. In Saudi Arabia, off-label drug use is:
- A) Completely prohibited
- B) Only allowed in research settings
- C) Freely permitted without any documentation
- D) Permitted when clinically justified, with proper informed consent and documentation
Explanation: Off-label use is not prohibited in Saudi Arabia but requires clinical justification, patient consent, and documentation in medical records. It is the prescriber's responsibility.
SECTION 4: Professional Ethics & Conduct (Q71-95)
Q71. A pharmaceutical sales representative offers a pharmacist a gift in exchange for preferentially recommending their product. Accepting this gift is:
- A) Acceptable if the gift is small
- B) Standard industry practice
- C) Acceptable if disclosed to the employer
- D) A conflict of interest and violation of professional ethics
Explanation: Accepting gifts from pharmaceutical representatives in exchange for preferential product recommendations violates pharmacy ethics and Saudi anti-corruption principles.
Q72. Patient confidentiality in Saudi pharmacy practice requires that:
- A) Information can be shared with family freely
- B) Prescription data can be shared with marketing companies
- C) Patient information is only confidential in hospitals
- D) All patient information must be kept strictly confidential unless disclosure is legally required or the patient consents
Explanation: Patient confidentiality is a fundamental ethical principle. Pharmacists must protect patient information under all circumstances except when legally compelled or with explicit patient consent.
Q73. A Muslim patient refuses a medication because it contains porcine-derived gelatin capsules. The pharmacist should:
- A) Insist the patient take the medication
- B) Tell the patient their concern is unfounded
- C) Refuse to help further
- D) Respect the patient's religious beliefs and explore alternative formulations or halal-certified products
Explanation: Respect for patient autonomy and religious beliefs is an ethical obligation. The pharmacist should seek alternative formulations (e.g., cellulose capsules, halal gelatin) and provide appropriate information.
Q74. The ethical principle that refers to doing good and acting in the patient's best interest is:
- A) Autonomy
- B) Justice
- C) Non-maleficence
- D) Beneficence
Explanation: Beneficence means acting in the patient's best interest and promoting their well-being - a core principle of healthcare ethics applied in Saudi pharmacy practice.
Q75. "First, do no harm" corresponds to which ethical principle?
- A) Beneficence
- B) Justice
- C) Autonomy
- D) Non-maleficence
Explanation: Non-maleficence ("primum non nocere" - first, do no harm) is the obligation to avoid causing harm to the patient, fundamental to pharmacy and all healthcare practice.
Q76. A pharmacist conscientiously objects to dispensing an oral contraceptive due to personal religious beliefs. In Saudi Arabia, the pharmacist should:
- A) Dispense but express their disapproval
- B) Never allow conscientious objection
- C) Simply refuse without any alternative
- D) Refer the patient to another pharmacist who can dispense the medication, ensuring patient access is not compromised
Explanation: While religious values are respected in Saudi culture, pharmacists must not abandon patients. If conscientious objection is exercised, a seamless referral must ensure the patient receives their medication.
Q77. Informed consent in pharmacy practice means the patient:
- A) Signs a form before receiving any medication
- B) Must have a guardian's consent for all medications
- C) Does not need to understand; signing is sufficient
- D) Understands the medication's purpose, side effects, and alternatives before agreeing to take it
Explanation: Informed consent requires that the patient understands the treatment - its nature, expected benefits, potential risks, and alternatives - before making a voluntary decision to proceed.
Q78. A pharmacist is aware that a colleague is practicing while impaired by alcohol. The pharmacist's ethical obligation is to:
- A) Ignore it as a personal matter
- B) Tell the patients only
- C) Confront the colleague privately and forget about it
- D) Report the colleague to the appropriate authority (SCFHS/hospital management) to protect patient safety
Explanation: Patient safety supersedes loyalty to colleagues. A pharmacist has an ethical and professional duty to report an impaired colleague to prevent potential harm.
Q79. The ethical principle of "justice" in pharmacy practice refers to:
- A) Reporting all crimes to the police
- B) Maximizing drug company profits
- C) Providing care only to paying patients
- D) Fair distribution of healthcare resources and treatment of all patients equitably
Explanation: Justice requires that pharmacists treat all patients fairly and equitably, and that healthcare resources are distributed without discrimination based on race, nationality, religion, or social status.
Q80. A pharmaceutical company invites a pharmacist to an all-expenses-paid conference that is primarily a marketing event. Accepting this invitation:
- A) Is perfectly ethical as it provides education
- B) Is required for professional development
- C) Is acceptable as the company benefits too
- D) May constitute a conflict of interest and should be carefully evaluated per professional ethics guidelines
Explanation: All-expenses-paid events that are primarily marketing in nature represent a conflict of interest. Professional ethics guidelines caution against arrangements that could unduly influence prescribing/dispensing.
Q81. A patient's diagnosis contains sensitive health information (e.g., HIV status). The pharmacist may share this information with:
- A) Any healthcare professional upon request
- B) Family members to ensure medication compliance
- C) Insurance companies automatically
- D) Only authorized healthcare team members directly involved in the patient's care, with patient consent
Explanation: Sensitive health information requires heightened confidentiality protection. It may only be shared on a need-to-know basis within the treating team, with the patient's consent when possible.
Q82. Which ethical framework aligns most closely with Islamic values and guides healthcare practice in Saudi Arabia?
- A) Utilitarianism exclusively
- B) Purely secular bioethics
- C) Only Western bioethical principles
- D) Islamic medical ethics (based on Sharia principles: preservation of life, health, intellect, progeny, and wealth)
Explanation: Islamic medical ethics, grounded in Sharia's five fundamental objectives (maqasid al-sharia), guides healthcare ethics in Saudi Arabia. These include preservation of life (nafs), intellect (aql), progeny (nasl), wealth (mal), and religion (din).
Q83. A pharmacist learns that a patient is taking a herbal remedy that interacts with their prescribed anticoagulant. The ethical duty is:
- A) Ignore herbal products as they are natural
- B) Only document in the record
- C) Tell only the physician, not the patient
- D) Counsel the patient on the interaction and communicate the concern to the prescribing physician
Explanation: Patient safety and beneficence require that pharmacists address all drug interactions including herbal-drug interactions through patient counseling and prescriber communication.
Q84. A pharmacist suspects a patient is misusing their prescribed benzodiazepine. The appropriate response is:
- A) Dispense without comment
- B) Refuse all future prescriptions
- C) Report to the police immediately without consultation
- D) Counsel the patient, consult the prescriber, and follow appropriate protocols including possible reporting if diversion is suspected
Explanation: Suspected drug misuse requires a professional, therapeutic approach: counsel the patient, communicate with the prescriber, and if drug diversion is suspected, follow reporting protocols.
Q85. Professional misconduct that can lead to suspension of a pharmacist's license in Saudi Arabia includes:
- A) Asking for prescription clarification
- B) Refusing to dispense a forged prescription
- C) Counseling patients on proper medication use
- D) Dispensing controlled substances without a valid prescription, fraudulent documentation, or practicing while impaired
Explanation: Serious professional violations such as illegal dispensing of controlled substances, documentation fraud, and impaired practice can result in SCFHS license suspension or revocation.
Q86. A patient requests that the pharmacist dispense their medication without the usual counseling as they are in a hurry. The pharmacist should:
- A) Always provide full counseling regardless of patient preference
- B) Skip counseling completely to respect autonomy
- C) Provide counseling only if the medication is new
- D) Respect the patient's autonomy while ensuring critical safety information is communicated, and offer written materials
Explanation: Balancing autonomy with beneficence - if a patient declines full counseling, the pharmacist should at minimum communicate critical safety points and provide written information.
Q87. In a hospital setting, a pharmacist who identifies an error in a physician's prescription should:
- A) Implement the change without telling the physician
- B) Refuse to dispense and document only
- C) Change the prescription to the correct dose
- D) Contact the physician, communicate the concern, and document the intervention
Explanation: Pharmacists cannot unilaterally change prescriptions. The correct approach is to communicate the concern to the prescriber, document the clinical intervention, and await authorization for any change.
Q88. Dual loyalty (conflicting obligations to employer and patient) is a recognized ethical challenge. If a pharmacy employer asks a pharmacist to dispense sub-standard products to save costs, the pharmacist should:
- A) Comply to keep their job
- B) Comply but inform patients
- C) Quit without reporting
- D) Refuse to comply, as the obligation to patient safety and professional ethics supersedes employer instructions
Explanation: Patient safety and professional ethics are non-negotiable. A pharmacist cannot compromise patient care quality due to employer or commercial pressure.
Q89. Which of the following represents the ethical principle of "autonomy" in pharmacy practice?
- A) The pharmacist decides what is best for the patient
- B) The physician's order always overrides patient choice
- C) Family members can make all decisions for adult patients
- D) Respecting the patient's right to make informed decisions about their own healthcare
Explanation: Patient autonomy means respecting each patient's right to make informed decisions about their own healthcare, including the right to refuse treatment after being properly informed.
Q90. A terminally ill patient in Saudi Arabia asks the pharmacist for information about the maximum dose of their pain medication. The pharmacist should:
- A) Refuse to answer any questions
- B) Provide full clinical information only via written form
- C) Report the patient to the physician for asking
- D) Provide appropriate information, ensure proper pain management coordination with the care team, and if concerned about intent, consult the palliative care team
Explanation: Pharmacists should support palliative and end-of-life care through appropriate information and coordination. Unusual questions about maximum dosing should involve the broader care team.
Q91. Which statement about research ethics in Saudi pharmacy is CORRECT?
- A) Patient consent is not required for clinical drug trials
- B) Institutional review board (IRB) approval is optional
- C) Placebo use is always unethical
- D) Any clinical research involving patients requires IRB/ethics committee approval and informed consent
Explanation: Clinical research in Saudi Arabia requires ethical review committee approval (IRB/Ethics Committee) and written informed consent from participants, following international GCP guidelines.
Q92. A pharmacist is asked to participate in a pharmaceutical company's post-market surveillance study. This is:
- A) Prohibited in Saudi Arabia
- B) Only allowed for senior pharmacists
- C) Always a conflict of interest
- D) Acceptable if conducted ethically with SFDA registration and patient consent
Explanation: Participating in legitimate pharmacovigilance/post-marketing studies is ethical and beneficial, provided proper regulatory registration, ethical approval, and patient consent are in place.
Q93. The "Four Principles" of biomedical ethics (Beauchamp and Childress) commonly applied in Saudi pharmacy education include all EXCEPT:
- A) Autonomy
- B) Beneficence
- C) Justice
- D) Accountability
Explanation: The four principles are Autonomy, Beneficence, Non-maleficence, and Justice. Accountability is an important professional value but is not one of the four principles of bioethical theory.
Q94. A pharmaceutical manufacturer provides direct financial support to a pharmacist's continuing education conference. This is:
- A) Always prohibited
- B) Mandatory for CE funding
- C) Completely unrestricted
- D) Acceptable only if disclosed and the content remains independent and unbiased
Explanation: Industry-funded CE is permissible but requires full disclosure of the funding source and independence of educational content from commercial promotion per professional ethics standards.
Q95. In Islamic medical ethics, the concept of "la darar wa la dirar" (do not harm and do not reciprocate harm) most closely aligns with:
- A) Beneficence
- B) Justice
- C) Autonomy
- D) Non-maleficence
Explanation: "La darar wa la dirar" is the Islamic principle of non-harm, directly corresponding to the bioethical principle of non-maleficence. It is a foundational concept in Islamic medical jurisprudence.
SECTION 5: Drug Pricing, Registration & Market Authorization (Q96-110)
Q96. A pharmaceutical product is approved by SFDA but the manufacturer has not submitted for drug pricing. The product:
- A) Can be sold at the manufacturer's desired price
- B) Can be sold with a temporary pricing
- C) Can only be dispensed in hospitals
- D) Cannot be marketed until SFDA approves the price
Explanation: In Saudi Arabia, pharmaceutical pricing is regulated by SFDA. Products cannot be marketed without an SFDA-approved price, even if the drug registration itself is complete.
Q97. The SFDA drug pricing methodology in Saudi Arabia is based on:
- A) Free market pricing
- B) Manufacturer's suggested retail price
- C) Import cost only
- D) Reference pricing compared to other countries, cost of goods, and affordability considerations
Explanation: SFDA uses a reference pricing system, comparing prices in reference countries and considering cost of goods, local affordability, and public health need when setting pharmaceutical prices.
Q98. A drug's price is set by SFDA at SAR 50. A pharmacy charges SAR 70. This represents:
- A) Acceptable profit margin
- B) Legitimate market pricing
- C) Standard pharmacy markup
- D) A violation of SFDA pricing regulations subject to penalties
Explanation: Pharmacies must adhere to SFDA-approved prices. Charging above the approved price is a regulatory violation subject to fines and penalties under Saudi regulations.
Q99. Which of the following products does NOT require SFDA registration in Saudi Arabia?
- A) Antidepressants
- B) Blood pressure medications
- C) Herbal supplements
- D) None of the above - all pharmaceutical and health products require SFDA registration
Explanation: All pharmaceutical, herbal, and health products including dietary supplements require SFDA registration before being marketed in Saudi Arabia.
Q100. A foreign drug is approved in the US (FDA) and Europe (EMA) but not registered in Saudi Arabia. A patient requests it. The pharmacist should:
- A) Import it directly for the patient
- B) Order it without registration if approved elsewhere
- C) Tell the patient to buy it abroad
- D) Not dispense unregistered products - refer to the physician who may apply for special import authorization through SFDA
Explanation: Unregistered drugs cannot be dispensed in Saudi Arabia. Patients who need unregistered drugs may access them through the SFDA's compassionate use or special import authorization process.
Q101. The SFDA's "Drug Approval Regulatory Framework" (2024) primarily aims to:
- A) Reduce the number of drugs available
- B) Increase drug prices
- C) Limit generic drug entry
- D) Streamline and accelerate drug approval processes while maintaining safety and efficacy standards
Explanation: The 2024 regulatory framework aims to improve efficiency of drug approvals in Saudi Arabia through reliance on trusted regulatory agencies, rolling reviews, and risk-based assessment.
Q102. A pharmacist discovers that a drug's batch number matches one announced in an SFDA recall notice. The correct action is:
- A) Continue dispensing if the medication looks fine
- B) Quarantine the product and wait for more information
- C) Return to supplier without notifying anyone
- D) Immediately quarantine the batch, stop dispensing, notify the supplier and relevant authorities, and follow SFDA recall procedures
Explanation: Upon identification of a recalled batch, the pharmacist must immediately quarantine it, cease dispensing, notify the supplier, and report to SFDA following the official recall management procedure.
Q103. In Saudi Arabia, biosimilar products must demonstrate:
- A) Only chemical similarity to the reference biologic
- B) Lower cost compared to the originator
- C) Same brand name as the reference
- D) Biosimilarity (analytical, non-clinical, and clinical comparative studies) to a reference biologic approved by SFDA
Explanation: Biosimilars must undergo a stepwise comparability exercise including analytical, non-clinical, and clinical studies to demonstrate biosimilarity to a reference product approved by SFDA, following the SFDA biosimilar guidelines.
Q104. Pharmacoeconomics in Saudi drug policy is primarily concerned with:
- A) Maximizing pharmaceutical sales
- B) Minimizing all drug expenditure regardless of outcomes
- C) Only drug acquisition costs
- D) Evaluating the clinical and economic value of drug therapies to inform formulary and reimbursement decisions
Explanation: Pharmacoeconomics evaluates the cost-effectiveness, cost-utility, and budget impact of medicines to support decision-making on drug formularies, reimbursement policies, and national drug selection.
Q105. Which organization manages the Saudi national formulary?
- A) SCFHS
- B) Saudi Pharmaceutical Society
- C) SFDA exclusively
- D) MOH with guidance from multiple stakeholders including SFDA
Explanation: The Saudi National Formulary is maintained by the MOH with involvement from SFDA, clinical experts, and other stakeholders to guide drug selection in government health facilities.
Q106. "Pharmaceutical equivalents" are products that:
- A) Have the same active ingredient but different indications
- B) Contain different active ingredients with same effect
- C) Are produced by the same manufacturer
- D) Contain the same active ingredient, same dosage form, route, and strength, meeting the same pharmacopeial standards
Explanation: Pharmaceutical equivalents contain the same active ingredient(s), in the same dosage form and strength, and meet the same official (pharmacopeial) standards. They may differ in inactive ingredients.
Q107. Which statement about drug patent protection in Saudi Arabia is CORRECT?
- A) Saudi Arabia does not recognize international drug patents
- B) Generic drugs can be marketed before patent expiry
- C) Patent protection is unlimited in Saudi Arabia
- D) Saudi Arabia recognizes drug patent protection; generics cannot be marketed until patent expiry without Bolar exemption provisions
Explanation: Saudi Arabia recognizes pharmaceutical patent protection under its intellectual property laws. Generic manufacturers cannot market products during the patent protection period without applicable legal provisions.
Q108. Under SFDA regulations, a pharmacist who wishes to compound a pharmaceutical preparation must:
- A) Use any available ingredients
- B) Only compound in hospital settings
- C) Not document the compounding process
- D) Follow SFDA compounding standards, use registered ingredients, maintain documentation, and compound only against a valid prescription or specific institutional need
Explanation: Pharmaceutical compounding in Saudi Arabia is regulated - pharmacists must follow SFDA standards for compounding, use quality ingredients, document the process thoroughly, and compound only for legitimate patient needs.
Q109. A drug product's shelf life and storage conditions are determined during:
- A) Post-marketing surveillance
- B) Clinical trials only
- C) Price negotiation with SFDA
- D) Stability testing conducted during drug development and registration
Explanation: Shelf life and storage conditions are determined through stability studies conducted during pharmaceutical development, per ICH guidelines, and are included in the SFDA registration dossier.
Q110. Which label statement is mandatorily required on pharmaceutical products sold in Saudi Arabia?
- A) Manufacturer's toll-free number only
- B) Only the brand name
- C) Price tag with no additional information
- D) Registration number, expiry date, batch number, storage conditions, in both Arabic and English
Explanation: Saudi regulations require pharmaceutical product labels to include registration number, expiry date, batch number, storage conditions, manufacturer information, and dosage instructions, in both Arabic and English.
SECTION 6: MOH Policies, Hospital Pharmacy & Patient Safety (Q111-130)
Q111. The "Do Not Use" abbreviation list in Saudi hospitals (per CBAHI/JCI standards) includes which commonly confused abbreviation?
- A) BID (twice daily)
- B) PO (by mouth)
- C) U (for units) - which may be misread as "0" causing 10-fold dosing errors
- D) SL (sublingual)
Explanation: "U" for units is on the "Do Not Use" abbreviation list because it can be misread as "0" or "4", potentially causing serious 10-fold dosing errors. "UNITS" must be written out in full.
Q112. Tall-man lettering in Saudi hospital pharmacies is used to:
- A) Make labels easier to print
- B) Increase storage capacity
- C) Label expired medications
- D) Differentiate look-alike/sound-alike (LASA) medications to prevent dispensing errors
Explanation: Tall-man lettering (e.g., "hydrALAzine" vs "hydrOXYzine") is an error-prevention strategy for look-alike/sound-alike drugs, used widely in Saudi hospital formulary management.
Q113. High-alert medications in Saudi hospitals are characterized by:
- A) High cost
- B) Need for refrigeration
- C) Rare adverse effects
- D) Heightened risk of causing significant patient harm when used in error
Explanation: High-alert medications (e.g., concentrated electrolytes, anticoagulants, insulin, chemotherapy) bear heightened risk of serious harm if misused and require specific safeguards per Saudi safety protocols.
Q114. Concentrated potassium chloride (KCl) injections in Saudi hospitals must be:
- A) Readily available in all medication carts
- B) Stocked in every ward for convenience
- C) Dispensed in unlabeled syringes
- D) Restricted to pharmacy, never stocked on wards - must be diluted before dispensing
Explanation: Concentrated KCl is a high-alert medication - it is prohibited from ward stock in Saudi hospitals per MOH patient safety standards. It must be prepared and dispensed as a diluted solution by pharmacy.
Q115. The Joint Commission International (JCI) and CBAHI National Patient Safety Goals relevant to pharmacy include all EXCEPT:
- A) Improving medication safety
- B) Correct patient identification before dispensing
- C) Reducing healthcare-associated infections
- D) Maximizing pharmaceutical company revenue
Explanation: National patient safety goals focus on patient safety outcomes (identification, medication safety, infection prevention, etc.), not pharmaceutical company revenue.
Q116. A medication error is defined in Saudi hospital practice as:
- A) Only errors resulting in patient harm
- B) Only errors made by pharmacists
- C) Prescribing errors only
- D) Any preventable event that may cause or lead to inappropriate medication use or patient harm
Explanation: A medication error includes any preventable event at any stage of the medication use process (prescribing, transcribing, dispensing, administration, or monitoring) that may or may not cause harm.
Q117. Adverse Drug Reaction (ADR) reporting in Saudi Arabia is submitted via which system?
- A) WHO VigiBase directly
- B) MOH hotline only
- C) SCFHS reporting portal
- D) SFDA's National Pharmacovigilance Centre (Nafdac/SFDA ADR reporting system)
Explanation: ADRs in Saudi Arabia are reported to the SFDA's National Pharmacovigilance Centre through the designated SFDA reporting portal/forms, which feeds into the WHO VigiBase.
Q118. Under Saudi hospital standards, medication reconciliation must occur:
- A) Only at hospital discharge
- B) Only on admission
- C) Only when a pharmacist is available
- D) At admission, transfer between care levels, and discharge
Explanation: Medication reconciliation is required at all transition points of care: admission, internal transfer, and discharge, to prevent medication errors during care transitions - a CBAHI/JCI requirement.
Q119. A pharmacist working in a Saudi hospital is part of the Pharmacy and Therapeutics (P&T) Committee. The primary function of this committee is:
- A) Managing pharmacy staff salaries
- B) Handling patient complaints
- C) Overseeing drug advertising
- D) Developing and maintaining the formulary, medication use policies, and promoting rational drug use
Explanation: The P&T Committee is responsible for the hospital formulary, medication use evaluation, drug use policies, and promoting safe and rational medication use within the hospital.
Q120. Unit dose dispensing in Saudi hospitals is preferred because it:
- A) Reduces pharmacist workload
- B) Increases the number of drugs stocked
- C) Allows nurses to prepare doses
- D) Reduces medication errors, improves dose accuracy, and facilitates patient billing
Explanation: Unit dose dispensing systems reduce dispensing errors by providing ready-to-administer individual patient doses, improve medication tracking, reduce waste, and facilitate accurate medication billing.
Q121. A pharmacist in a Saudi ICU identifies that a patient is receiving a nephrotoxic drug (aminoglycoside) without therapeutic drug monitoring (TDM). The correct action is:
- A) Continue the prescription as ordered
- B) Increase the dose to compensate
- C) Stop the drug unilaterally
- D) Recommend TDM to the treating team and document the clinical pharmacist intervention
Explanation: Clinical pharmacists have a key role in recommending TDM for narrow-therapeutic-index drugs. The recommendation is made to the treating team (not unilaterally implemented), and the intervention is documented.
Q122. In Saudi Arabia, the medical error disclosure obligation requires:
- A) Only reporting to hospital administration
- B) Disclosure only if the patient demands it
- C) No mandatory disclosure
- D) Transparent disclosure to the patient and family when a medical/medication error causes harm
Explanation: Saudi healthcare accreditation standards and ethical obligations require transparent disclosure of medical and medication errors that cause harm to patients and their families.
Q123. A pharmacist refuses to participate in a "buy more, get a free gift" promotion for a prescription medication in a hospital pharmacy. This reflects:
- A) Excessive caution
- B) Financial mismanagement
- C) Poor customer service
- D) Appropriate professional behavior, as inducements for prescription drug use are unethical
Explanation: Commercial promotions that incentivize patients to use specific prescription medications without clinical indication are unethical and contrary to rational drug use principles.
Q124. The correct definition of "Drug Utilization Review" (DUR) in Saudi pharmacy practice is:
- A) Annual drug inventory review
- B) Financial audit of drug spending
- C) Review of drugs near expiry
- D) Ongoing, authorized, and prospective or retrospective review of drug therapy to ensure appropriate use
Explanation: DUR is a systematic process to assess the appropriateness, safety, and cost-effectiveness of drug use against established clinical standards, used extensively in Saudi hospital quality programs.
Q125. Which of the following is a MOH requirement for safe vaccine storage in Saudi community pharmacies?
- A) Room temperature storage is acceptable for all vaccines
- B) Any refrigerator can be used for vaccine storage
- C) Vaccines can be stored with food products
- D) Dedicated pharmaceutical-grade refrigerator maintaining 2-8°C, with temperature monitoring and no food/other items
Explanation: Vaccines must be stored in dedicated pharmaceutical-grade refrigerators at 2-8°C with continuous temperature monitoring, logs, and no non-pharmaceutical items per MOH cold chain management requirements.
Q126. Antimicrobial stewardship programs (ASP) in Saudi hospitals include pharmacist participation in:
- A) Selling antibiotics to patients
- B) Dispensing all antibiotics without restriction
- C) Only documentation of antibiotic use
- D) Reviewing antibiotic prescriptions, recommending de-escalation, IV to oral conversion, and optimal dosing based on cultures and sensitivity
Explanation: Pharmacists are integral to antimicrobial stewardship programs, reviewing appropriateness of antibiotic use, recommending de-escalation when cultures return, suggesting IV-to-oral conversion, and optimizing dosing.
Q127. Under CBAHI standards, "time-out" in the context of high-risk medication administration refers to:
- A) A break for pharmacy staff
- B) Time limit for drug administration
- C) Delay before IV drug preparation
- D) A verification pause before administering high-risk medications to confirm right patient, drug, dose, route, and time
Explanation: "Time-out" for high-risk medications is a patient safety practice requiring a verification pause (checking the 5 rights: patient, drug, dose, route, time) before administration of high-alert medications.
Q128. A Saudi hospital policy states "No verbal orders for chemotherapy agents." This policy is designed to:
- A) Reduce workload for physicians
- B) Save documentation time
- C) Allow pharmacists more autonomy
- D) Prevent errors that occur with verbal orders for high-alert oncology medications
Explanation: Prohibiting verbal orders for chemotherapy prevents misunderstandings in drug names, doses, and routes - a critical patient safety measure given the narrow therapeutic index and high toxicity of oncology agents.
Q129. Which of the following best describes "pharmacogenomics" relevance in Saudi pharmacy practice?
- A) No relevance as it is experimental
- B) Only relevant for research pharmacists
- C) Applies only to oncology medications
- D) Using genetic information to personalize drug selection and dosing for optimal therapeutic outcomes and minimal adverse effects
Explanation: Pharmacogenomics involves using patients' genetic profiles to optimize drug therapy - increasingly relevant in Saudi precision medicine initiatives, particularly for oncology, cardiovascular, and psychiatric medications.
Q130. The "5 Rights" of medication administration critical to pharmacy practice are:
- A) Right patient, right drug, right dose, right time, right cost
- B) Right drug, right dose, right form, right speed, right time
- C) Right patient, right drug, right dose, right route, right pharmacist
- D) Right patient, right drug, right dose, right route, right time
Explanation: The 5 Rights of medication administration are: Right Patient, Right Drug, Right Dose, Right Route, and Right Time - the foundational safety checklist for medication dispensing and administration in Saudi healthcare.
SECTION 7: Saudi Health System, SCFHS & Professional Licensing (Q131-150)
Q131. The SCFHS classification levels for pharmacists in Saudi Arabia include all EXCEPT:
- A) Resident
- B) Specialist
- C) Consultant
- D) Professor (academic rank, not an SCFHS clinical classification)
Explanation: SCFHS clinical classification levels include Resident, Specialist (General and Senior), and Consultant. "Professor" is an academic title assigned by universities, not a clinical SCFHS classification.
Q132. A pharmacist from Egypt wishes to practice in Saudi Arabia. Their primary qualification is a Bachelor of Pharmacy from an Egyptian university. Which pathway does SCFHS use?
- A) Automatic registration based on Arab world qualification
- B) No registration needed for Arab nationals
- C) Direct employment without examination
- D) Credential verification, SCFHS classification, and passing the Saudi Pharmacy Licensing Examination (SPLE)
Explanation: All foreign pharmacists, including those from Arab countries, must have their credentials verified, be classified by SCFHS, and pass the SPLE before they can be licensed to practice in Saudi Arabia.
Q133. The Vision 2030 health sector initiative in Saudi Arabia aims to achieve which goal regarding pharmacy?
- A) Decrease the number of pharmacists
- B) Replace pharmacists with automated systems
- C) Limit pharmacy services to dispensing only
- D) Enhance pharmaceutical care quality, increase Saudi pharmacist numbers, and integrate pharmacy into healthcare teams
Explanation: Saudi Vision 2030 health goals include improving pharmaceutical care quality, increasing Saudi national healthcare professionals (Saudization), and developing pharmacy practice toward clinical and patient-centered models.
Q134. The National Transformation Program (NTP) health targets related to pharmacy include:
- A) Reducing pharmacy education programs
- B) Eliminating private pharmacy sector
- C) Centralizing all pharmaceutical decisions
- D) Improving medication safety indicators, expanding pharmaceutical care services, and increasing pharmacist participation in clinical teams
Explanation: The NTP targets for health include measurable pharmacy quality improvements, expanded pharmaceutical care, better medication safety outcomes, and increased clinical pharmacist integration.
Q135. A pharmacist's SCFHS registration has expired. They continue practicing. This constitutes:
- A) A minor administrative issue
- B) Acceptable if renewing soon
- C) Only a financial penalty matter
- D) Illegal practice without a valid license, subject to serious legal and professional penalties
Explanation: Practicing with an expired SCFHS license is illegal in Saudi Arabia - it constitutes unlicensed practice of pharmacy, which is subject to criminal penalties and loss of future registration.
Q136. Which of the following is a requirement for Saudi Pharmacy Licensing Examination (SPLE)?
- A) Saudi nationality
- B) Minimum 5 years of experience
- C) Recommendation from a physician
- D) Valid pharmacy degree from an accredited institution and SCFHS eligibility approval
Explanation: SPLE candidates must hold a pharmacy degree from an SCFHS-recognized institution and receive eligibility approval from SCFHS before sitting the examination, regardless of nationality.
Q137. Hospital pharmacy directors in Saudi MOH hospitals are required to be:
- A) Any licensed physician
- B) A senior administrator
- C) An MOH-appointed non-pharmacist
- D) A licensed pharmacist with relevant qualification and experience
Explanation: Hospital pharmacy directors in Saudi Arabia must be licensed pharmacists with appropriate qualifications, as the pharmacy department director holds professional and legal responsibility for pharmaceutical services.
Q138. Saudi Saudization (Nitaqat) policy affects pharmacy practice by:
- A) Banning all foreign pharmacists
- B) Having no impact on pharmacy staffing
- C) Only affecting pharmacy management positions
- D) Requiring healthcare facilities to meet specified percentages of Saudi national pharmacists and technicians in their workforce
Explanation: The Nitaqat (Saudization) program requires all private sector healthcare facilities to maintain specific percentages of Saudi nationals in their workforce, including pharmacy departments, with tiered compliance categories.
Q139. A foreign-trained pharmacist seeking equivalency of their degree in Saudi Arabia must apply to:
- A) SFDA
- B) The ministry of their home country
- C) Saudi Embassies abroad
- D) SCFHS for credential evaluation and equivalency assessment
Explanation: Degree equivalency for foreign-trained health professionals is processed by SCFHS, which evaluates the institution's accreditation status and the applicant's qualifications against Saudi standards.
Q140. Anti-corruption regulations in Saudi Arabia (governed by the National Anti-Corruption Commission - Nazaha) apply to pharmacists by:
- A) Only covering government employees
- B) Not applicable to healthcare
- C) Only covering procurement decisions
- D) Prohibiting bribery, conflict of interest, and corruption in both public and private healthcare settings
Explanation: Saudi anti-corruption laws (enforced by Nazaha) apply to all sectors including healthcare, prohibiting bribery, kickbacks, and conflicts of interest for both government and private sector pharmacists.
Q141. The Electronic Prescribing and Dispensing System (MAWID/NPHIES) in Saudi Arabia aims to:
- A) Replace pharmacists with AI dispensing
- B) Only track narcotic prescriptions
- C) Generate pharmacy revenue reports
- D) Integrate prescribing, dispensing, and patient records across the healthcare system to improve safety and efficiency
Explanation: Saudi Arabia's National Platform for Health Information Exchange (NPHIES) integrates healthcare data including prescribing and dispensing records to improve medication safety, reduce duplication, and support coordinated care.
Q142. The Saudi Drug and Narcotic Control Committee (under MOH) is responsible for:
- A) Drug pricing decisions
- B) Pharmacist licensing
- C) Drug manufacturing approval
- D) Overseeing narcotic and psychotropic substance policies, allocations, and monitoring at the national level
Explanation: The Saudi Drug and Narcotic Control Committee coordinates national policy on narcotic and psychotropic substances, including allocation of controlled substance quotas, policy development, and monitoring.
Q143. Which statement about pharmacy practice in the MOH's Primary Healthcare Centers (PHCs) is CORRECT?
- A) Pharmacists are not required in PHCs
- B) PHC pharmacists cannot provide medication counseling
- C) Prescription review is optional in PHCs
- D) Pharmacists in PHCs provide dispensing, counseling, medication management, and health promotion services
Explanation: PHC pharmacists in Saudi Arabia play an expanding role including dispensing, patient counseling, chronic disease medication management (diabetes, hypertension), and health education, per MOH PHC guidelines.
Q144. The Saudi Patient Rights Charter guarantees patients which of the following regarding medications?
- A) The right to choose any drug without prescription
- B) The right to refuse pharmacist counseling permanently
- C) Right to medication without informed consent
- D) The right to be fully informed about their medications, the right to refuse treatment, and confidentiality of health information
Explanation: The Saudi Patient Rights Charter, consistent with MOH and healthcare accreditation standards, guarantees patients: the right to information about their treatment, the right to refuse treatment, and the right to confidentiality.
Q145. Pharmaceutical advertising directed at healthcare professionals in Saudi Arabia must:
- A) Include no clinical data
- B) Be approved by the manufacturer only
- C) Not reference SFDA registration status
- D) Be approved by SFDA, contain accurate clinical information, and not be misleading
Explanation: Pharmaceutical advertising to healthcare professionals must be SFDA-approved, factually accurate, based on evidence, and not misleading - as per SFDA advertising and promotion guidelines.
Q146. A pharmacist working in a Saudi oncology center must have awareness of SFDA requirements for which specific drug handling concern?
- A) Antibiotic stewardship
- B) Vaccine cold chain
- C) OTC drug pricing
- D) Cytotoxic drug handling, preparation safety, and SFDA special authorization requirements for oncology agents
Explanation: Cytotoxic drugs require specialized handling (negative pressure isolators, PPE), preparation protocols, staff training, and specific SFDA regulatory compliance for their importation, storage, and use.
Q147. In a Saudi community pharmacy, a child's parent asks the pharmacist to recommend a cough syrup for their 18-month-old. The pharmacist should:
- A) Recommend the most potent OTC cough syrup
- B) Recommend an antibiotic syrup
- C) Recommend an adult cough syrup in a smaller dose
- D) Advise against OTC cough suppressants in children under 2, recommend honey-based preparations if appropriate, and suggest physician consultation for persistent cough
Explanation: Saudi health guidelines, consistent with international evidence, discourage OTC cough and cold medications in children under 2 years due to safety concerns. The pharmacist's role is to provide safe, evidence-based guidance.
Q148. The MOH "Rational Drug Use" (RDU) policy in Saudi Arabia promotes:
- A) Maximizing drug prescribing
- B) Using the most expensive available drug
- C) Self-medication with prescription drugs
- D) Prescribing and dispensing the right drug, at the right dose, for the right duration, to the right patient, at the right time and cost
Explanation: Saudi MOH's Rational Drug Use policy aligns with WHO principles: ensuring medications are clinically appropriate, used correctly, and cost-effective - combating overuse, underuse, and misuse of medicines.
Q149. A pharmacist in Saudi Arabia receives a complaint from a patient about poor counseling received at another pharmacy. The correct response is to:
- A) Defend the other pharmacist automatically
- B) Ignore the complaint as it is not their pharmacy
- C) Report the other pharmacist to SFDA
- D) Counsel the patient appropriately now, and advise them they can report concerns to SCFHS or MOH patient relations department
Explanation: The immediate priority is caring for the patient at hand. For complaints about other providers, patients should be directed to SCFHS or the MOH patient relations system for formal complaint resolution.
Q150. The future direction of pharmacy practice in Saudi Arabia under Vision 2030 includes all of the following EXCEPT:
- A) Expanding clinical pharmacy roles in hospitals
- B) Integrating pharmacists into multidisciplinary teams
- C) Developing telepharmacy and digital health services
- D) Restricting pharmacy practice exclusively to dispensing functions
Explanation: Vision 2030 drives pharmacy practice forward toward clinical, patient-centered, and technology-integrated models. Restricting pharmacy to only dispensing contradicts the strategic direction of expanding pharmaceutical care in Saudi Arabia.
Quick Reference Summary of Key Saudi Pharmacy Regulatory Bodies
| Body | Primary Function |
|---|---|
| SFDA | Drug registration, pricing, market authorization, pharmacovigilance, narcotic import/export |
| SCFHS | Pharmacist licensing, classification, CPD, professional discipline |
| MOH | Pharmacy facility licensing, national drug policy, PHC services, narcotic policy |
| CBAHI | Hospital accreditation including pharmacy standards |
| Nazaha | Anti-corruption enforcement in healthcare |
Key Numbers to Remember:
- SFDA established: 2003
- Drug registration validity: 5 years
- Narcotic prescription: single use, no refills
- Labels: Arabic + English (mandatory)
- Narcotic custodian: must be Saudi national
- Traveler's personal medication: max 1-month supply with SFDA permit
- Pharmacy director: must be a licensed pharmacist
These 150 MCQs cover SFDA regulations, controlled substances law, pharmacy practice law, professional ethics, drug registration and pricing, hospital pharmacy standards, patient safety, narcotic dispensing rules, and Saudi Vision 2030 health policies - all high-yield topics for the Saudi Pharmacy Licensing Examination (SPLE). Each question includes an explanation to reinforce the rationale behind the correct answer.
This is a shared conversation. Sign in to Orris to start your own chat.